Clinical trials recruiting for NSCLC Stage IV

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
  NCT07548060 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
  NCT05543330 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
  NCT05657873 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
  NCT06512207 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: Male · 1 location
• AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
  NCT06788366 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
  NCT05281406 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
  NCT06745908 · Phase: Phase 3 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 36 locations
• Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
  NCT04467723 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
  NCT06501378 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
  NCT06532149 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: Male · 1 location
• Lung Cancer Registry
  NCT04654364 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
  NCT05701787 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy
  NCT06436625 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
  NCT04136535 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
  NCT05950139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
  NCT06552234 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
  NCT06401824 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
  NCT06523673 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
  NCT07279402 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
  NCT05332925 · Phase: Not specified · Ages: 18 Years to 110 Years · Sex: All (male and female) · 2 locations

Related conditions

Trials recruiting for NSCLC Stage IV often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for NSCLC Stage IV trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.